Lisata Therapeutics (LSTA) to Release Quarterly Earnings on Tuesday

Lisata Therapeutics (NASDAQ:LSTA) is set to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Lisata Therapeutics to post earnings of ($0.75) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.14. During the same quarter in the previous year, the business earned ($0.50) earnings per share. On average, analysts expect Lisata Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lisata Therapeutics Stock Performance

NASDAQ LSTA opened at $2.91 on Friday. Lisata Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $3.83. The firm has a market capitalization of $24.21 million, a P/E ratio of -1.13 and a beta of 1.22. The stock has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.08.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, September 18th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.